ArticleCureus2026
Outcomes of Two-Stage Total Hip Replacement for Infected Hemiarthroplasty.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Infection following hemiarthroplasty of the hip is a devastating complication associated with significant morbidity. While two-stage revision total hip replacement (THR) is the gold standard for chronic periprosthetic joint infection (PJI) in total hip arthroplasty, literature focusing on infected hemiarthroplasty remains limited. This study evaluates the clinical, functional, and radiological outcomes of two-stage revision THR in patients with infected hemiarthroplasty. This retrospective level IV study, conducted in a single center, included 23 patients with confirmed PJI following hemiarthroplasty who underwent two-stage revision THR between January 2015 and January 2024 with a minimum follow-up of two years. Infection was diagnosed using the updated 2018 Musculoskeletal Infection Society (MSIS) criteria. The first stage involved implant removal, debridement, and placement of an antibiotic-loaded cement spacer, followed by targeted antibiotic therapy. Reimplantation was performed after five to seven weeks. Functional outcomes were assessed using the Harris hip score (HHS), and radiological evaluation assessed implant stability. Statistical analysis was performed using a paired t-test. The cohort included 14 females and 9 males, with a mean age of 65.96 years. The mean HHS improved significantly from 26.65 preoperatively to 80.52 postoperatively (p < 0.0001). Infection was eradicated in 95.7% of patients, with one case (4.3%) of recurrent infection. Additionally, 52% of the patients were walking without support, 35% of the patients were using one stick for taking long walks, and 13% of patients always required stick support in the last follow-up. No dislocations, aseptic loosening, or implant migration were observed. There was one intraoperative periprosthetic fracture, which was successfully managed. Two-stage revision THR was associated with high infection-control rates and functional improvement in this series of infected hemiarthroplasty patients and remains a reliable treatment strategy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.